ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW

enGene Therapeutics Inc.

Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 8, 2026

$1.58−0.09 (-5.39%)

Close on Oct 19, 2026

Market cap: $110.18M
P/E (TTM): 0.7
Dividend yield: 0.00%

enGene Therapeutics Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	Q3 2026 2026-07-31	Q2 2026 2026-04-30	Q1 2026 2026-01-31	Q4 2025 2025-10-31	Q3 2025 2025-07-31	Q2 2025 2025-04-30	Q1 2025 2025-01-31	Q4 2024 2024-10-31	Q3 2024 2024-07-31	Q2 2024 2024-04-30	Q1 2024 2024-01-31	Q4 2023 2023-10-31	Q3 2023 2023-07-31	Q2 2023 2023-04-30	Q1 2023 2023-01-31	Q4 2022 2022-10-31	Q4 2021 2021-10-31
Cash & Equivalents	41	30	37	50	33	58	62	173	258	265	86	82	–	–	–	20	11
Short-Term Investments	225	229	239	144	169	160	151	65	–	–	–	–	–	–	–	–	–
Cash & Short-Term Investments	266	258	276	194	202	217	214	238	258	265	86	82	–	–	–	20	11
Prepaid Expenses & Other	11	11	12	6.65	8.62	9.98	8.00	8.63	4.70	3.51	2.72	1.50	–	–	–	0.74	–
Total Current Assets	278	270	289	201	211	228	222	247	263	270	90	85	–	–	–	23	–
Property, Plant & Equipment	2.16	2.34	2.44	2.48	1.88	1.55	1.37	1.17	1.01	1.11	0.99	0.59	–	–	–	0.39	–
Gross Property, Plant & Equipment	4.79	4.79	4.73	4.58	3.81	3.37	3.08	2.78	2.54	2.99	2.80	2.32	–	–	–	1.94	–
Accumulated Depreciation	-2.63	-2.46	-2.29	-2.10	-1.93	-1.82	-1.71	-1.61	-1.53	-1.89	-1.81	-1.73	–	–	–	-1.55	–
Long-Term Investments	0	27	37	8.52	23	34	59	60	–	–	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	6.88	7.11	7.47	7.72	7.97	1.64	1.69	1.74	1.79	1.84	1.88	–	–	–	–	–	–
Other Long-Term Assets	1.39	1.38	1.39	1.36	1.38	1.38	1.58	1.37	1.38	0.98	0.97	0.93	–	–	–	0.94	–
Total Assets	288	308	337	221	246	267	286	311	267	274	93	87	–	–	–	24	–
Accounts Payable	2.54	1.79	2.44	6.69	2.38	1.57	2.61	1.41	2.86	0.21	1.28	1.16	–	–	–	0.72	–
Current Portion of Leases	2.25	2.29	2.32	2.01	1.53	0.43	0.42	0.42	0.42	0.42	0.39	–	–	–	–	–	–
Current Income Taxes Payable	–	–	–	0.02	0.57	0.33	0.09	–	–	0.03	0.01	0.04	–	–	–	0.02	–
Total Current Liabilities	27	21	25	32	20	18	13	15	13	6.30	6.91	5.26	–	–	–	5.10	–
Long-Term Debt	25	25	25	15	18	20	22	22	22	23	23	9.22	–	–	–	9.65	–
Long-Term Leases	5.67	5.96	6.22	6.46	6.73	1.34	1.33	1.43	1.48	1.53	1.60	–	–	–	–	–	–
Operating Lease Liabilities	7.92	8.25	8.54	8.47	8.26	1.77	1.75	1.80	1.90	1.95	2.00	0	–	–	–	–	–
Total Liabilities	58	52	56	54	45	39	36	39	37	31	31	14	–	–	–	47	–
Total Debt	25	25	25	15	18	20	22	22	22	23	23	9.22	–	–	–	9.65	–
Common Stock	632	632	632	513	510	510	510	510	453	453	259	259	–	–	–	16	–
Additional Paid-In Capital	64	56	52	27	26	23	21	19	17	16	14	14	–	–	–	7.68	–
Retained Earnings	-465	-432	-402	-372	-334	-305	-279	-255	-239	-225	-210	-200	–	–	–	-100	–
Comprehensive Income & Other	-1.35	-1.14	-0.84	-0.89	-1.21	-0.97	-1.28	-1.42	-1.02	-1.02	-1.02	-1.02	–	–	–	-1.02	–
Shareholders' Equity	230	255	282	168	201	227	250	273	230	243	62	72	-94	-89	-84	-77	-53
Total Equity	230	255	282	168	201	227	250	273	230	243	62	72	-94	-89	-84	-77	-53
Total Liabilities & Equity	288	308	337	221	246	267	286	311	267	274	93	87	–	–	–	24	–
Shares Outstanding(shares)	67	67	67	52	51	51	51	51	44	44	23	23	–	–	–	0.67	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jul 31, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -53.3%

Financial strength

Current ratio: 10.21
Debt to equity: 0.11
Debt to assets: 8.7%
Cash to current liabilities: 150.8%

Valuation

P/E ratio: 0.7
Price to sales: –
Price to book: 0.48
Dividend yield: 0.00%